COMMUNIQUÉS West-GlobeNewswire

EyePoint Pharmaceuticals Announces Third Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information

19/04/2018 - 13:00

Conference Call Scheduled for 4:30 p.m. ET on Tuesday, May 8th WATERTOWN, Mass., April 19, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT ) (ASX:PVA), a specialty biopharmaceutical company [...]

NeuroMetrix Reports Q1 2018 Financial Results

19/04/2018 - 13:00

GlaxoSmithKline Collaboration is Quarter Highlight WALTHAM, Mass., April 19, 2018 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO ), today reported financial and business highlights for the quarter ended March 31, [...]

Axsome Therapeutics Appoints Nick Pizzie, CPA, MBA, as Chief Financial Officer

19/04/2018 - 13:00

NEW YORK, April 19, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM ), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders [...]

miRagen Therapeutics to Present New Preclinical Data at the Wound Healing Society and the Association for Research in Vision and Ophthalmology Annual Meetings

19/04/2018 - 13:00

BOULDER, Colo., April 19, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN ), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced [...]

Capricor Announces New Pre-Clinical Study Finds Repeat Doses of CAP-1002 Lead to Enhanced Exercise Capacity in Duchenne Muscular Dystrophy Disease Model

19/04/2018 - 13:00

Findings are the Basis for the HOPE-2 Clinical Trial LOS ANGELES, April 19, 2018 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR ) today announced that researchers found that repeat dosing of the company’s [...]

Merus to Report Full Year 2017 Financial Results and Corporate Developments on April 26, 2018

19/04/2018 - 13:00

Conference call scheduled for Thursday, April 26, 2018, at 8:30 a.m. ET UTRECHT, The Netherlands, April 19, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS ), a clinical-stage immuno-oncology company developing [...]

XORTX Announces PKD Foundation Collaboration

19/04/2018 - 13:00

CALGARY, Alberta, April 19, 2018 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE:XRX) is pleased to announce that the PKD Foundation has recognized XORTX as a leader in advancing the [...]

Summit Completes Dosing of Ezutromid in PhaseOut DMD Clinical Trial

19/04/2018 - 13:00

Top-line Data On-track to be Reported During Q3 2018 OXFORD, United Kingdom and CAMBRIDGE, Mass., April 19, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ: SMMT ) (AIM:SUMM) announces the completion of [...]

Emergent BioSolutions to Release First Quarter 2018 Financial Results and Conduct a Conference Call on May 3, 2018

19/04/2018 - 12:30

GAITHERSBURG, Md., April 19, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS ) will host a conference call on Thursday, May 3, 2018 at 5:00 pm (Eastern Time) to discuss the financial results for the first [...]

This Week in the News: A Curated Selection of the Best Media Coverage on PotNetwork Holdings, Inc.

19/04/2018 - 12:00

PotNetwork Holdings, Inc. featured in International Business Times, Small Cap Network, Born2Invest, Natural Way & Ultra Meds Global FT LAUDERDALE, Fla., April 19, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- [...]

Adamas Announces Final Results from the Two-Year Phase 3 Open-Label Study of GOCOVRI™ in Parkinson’s Disease Patients with Dyskinesia

19/04/2018 - 11:30

-- Patients receiving GOCOVRI experienced long-term durability for up to two years -- -- Safety profile was consistent with previously-published controlled Phase 3 studies -- EMERYVILLE, Calif., April 19, 2018 (GLOBE [...]

Oasmia has completed a private placement of new convertible instruments in a total amount of SEK 26,000,000

19/04/2018 - 08:45

Uppsala, Sweden April 19, 2018 – Oasmia Pharmaceutical AB (publ) (“Oasmia” or the “Company”) hereby announces that the Company has completed a private placement of a convertible loan in the amount of SEK 26,000,000 with [...]

Motif Bio Announces New Iclaprim Data being Presented at ECCMID 2018

19/04/2018 - 08:00

NEW YORK, April 19, 2018 (GLOBE NEWSWIRE) -- Positive efficacy and safety highlights from Phase 3 REVIVE-2 trial in ABSSSI Potential to avoid costs related to vancomycin-associated acute kidney injury in ABSSSI Data [...]

Herantis Pharma awarded Innovation prize of the Chemical Industry Federation of Finland

19/04/2018 - 07:30

Herantis Pharma awarded Innovation prize of the Chemical Industry Federation of Finland Herantis Pharma Plc Press release 19 Apr 2018 at 8:30 am The Innovation prize 2018 of Finland's Chemical Industry Federation was [...]

Novartis appoints John Tsai Head of Global Drug Development and Chief Medical Officer

19/04/2018 - 07:16

Basel, April 19, 2018 - Novartis announced today the appointment of John Tsai, M.D. as Head of Global Drug Development (GDD) and Chief Medical Officer. Dr. Tsai will join Novartis on May 1, 2018, and will be based in [...]

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

19/04/2018 - 07:06

REGULATED INFORMATION GHENT, Belgium, 19 April 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]

Novartis delivered a strong first quarter and acted to become a more focused medicines company

19/04/2018 - 07:02

Net sales grew 4% (cc[1], +10% USD) mainly driven by: Entresto grew to USD 200 million, +126% (cc) driven by increased uptake world wide Cosentyx was USD 580 million, +35% (cc) with strong growth in all indications and [...]

Novartis a réalisé une bonne performance au premier trimestre et agi pour devenir une entreprise plus centrée sur les médicaments

19/04/2018 - 07:02

Hausse du chiffre d'affaires net de 4% (tcc[1], +10% USD), stimulée principalement par: Entresto , qui a atteint USD 200 millions, soit +126% (tcc), soutenu par son adoption croissante dans le monde entier Cosentyx qui [...]

Curetis Launches CE-IVD Marked Unyvero Urinary Tract Infection (UTI) Cartridge at ECCMID 2018

19/04/2018 - 07:02

Curetis Launches CE-IVD Marked Unyvero Urinary Tract Infection (UTI) Cartridge at ECCMID 2018 UTI panel covers 103 diagnostic targets 443-patient multi-center study demonstrates overall weighted average sensitivity of [...]